PFE’s profit share on Enbrel sales in US/Canada is replaced by a declining royalty scheme starting in late 2013 and lasting through 2015, according to AMGN’s JPM webcast.
PFE will retain its full ex-North America rights on Enbrel.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”